Silvana Martino

Summary

Publications

  1. ncbi request reprint Safety assessment of raloxifene over eight years in a clinical trial setting
    Silvana Martino
    The Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Curr Med Res Opin 21:1441-52. 2005
  2. ncbi request reprint Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    Silvana Martino
    Cancer Institute Medical Group, 2001 Santa Monica Blvd, Ste 560W, Santa Monica, CA 90404, USA
    J Natl Cancer Inst 96:1751-61. 2004
  3. doi request reprint Prognostic value of basal phenotype in HER2-overexpressing breast cancer
    Sanjay P Bagaria
    Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA
    Ann Surg Oncol 19:935-40. 2012
  4. doi request reprint Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women
    Olga M Olevsky
    Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Menopause 15:790-6. 2008
  5. ncbi request reprint The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials
    Silvana Martino
    The John Wayne Cancer Institute, St Johns Health Center, Santa Monica, California, USA
    Oncologist 9:116-25. 2004
  6. ncbi request reprint Prediction of breast tumor progression by integrity of free circulating DNA in serum
    Naoyuki Umetani
    Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 24:4270-6. 2006
  7. ncbi request reprint Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk
    Marc E Lippman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:5242-7. 2006
  8. ncbi request reprint Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
  9. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
  10. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Safety assessment of raloxifene over eight years in a clinical trial setting
    Silvana Martino
    The Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Curr Med Res Opin 21:1441-52. 2005
    ..The aim of this study was to assess the safety of raloxifene over 8 years in 4011 postmenopausal women with osteoporosis in a clinical trial setting through adverse event reporting...
  2. ncbi request reprint Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene
    Silvana Martino
    Cancer Institute Medical Group, 2001 Santa Monica Blvd, Ste 560W, Santa Monica, CA 90404, USA
    J Natl Cancer Inst 96:1751-61. 2004
    ..We conducted the Continuing Outcomes Relevant to Evista (CORE) trial to examine the effect of 4 additional years of raloxifene therapy on the incidence of invasive breast cancer in women in MORE who agreed to continue in CORE...
  3. doi request reprint Prognostic value of basal phenotype in HER2-overexpressing breast cancer
    Sanjay P Bagaria
    Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA
    Ann Surg Oncol 19:935-40. 2012
    ..We investigated the clinical relevance of this basal-HER2+ subtype within HER2-overexpressing breast tumors...
  4. doi request reprint Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women
    Olga M Olevsky
    Angeles Clinic and Research Institute, Santa Monica, CA 90404, USA
    Menopause 15:790-6. 2008
    ..It has a more favorable toxicity profile than tamoxifen and provides an alternative for postmenopausal women...
  5. ncbi request reprint The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials
    Silvana Martino
    The John Wayne Cancer Institute, St Johns Health Center, Santa Monica, California, USA
    Oncologist 9:116-25. 2004
    ..Completion of these trials will provide important information about the occurrence of invasive breast cancer in postmenopausal women and the efficacy of raloxifene for breast cancer risk reduction...
  6. ncbi request reprint Prediction of breast tumor progression by integrity of free circulating DNA in serum
    Naoyuki Umetani
    Department of Molecular Oncology and the Joyce Eisenberg Breast Center, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
    J Clin Oncol 24:4270-6. 2006
    ..Serum DNA integrity, the ratio of longer fragments to total DNA, may be clinically useful for detecting breast cancer progression...
  7. ncbi request reprint Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk
    Marc E Lippman
    Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:5242-7. 2006
    ..To assess the effect of raloxifene, indicated for osteoporosis treatment and prevention, on invasive breast cancer in subgroups of postmenopausal women defined by risk factors for breast cancer...
  8. ncbi request reprint Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17
    Edith A Perez
    St Michael s Hospital, Toronto, Canada
    J Clin Oncol 24:3629-35. 2006
    ..17B evaluated bone turnover markers and bone mineral density (BMD) in postmenopausal women randomly assigned to MA.17, a placebo-controlled trial of letrozole after standard adjuvant tamoxifen...
  9. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  10. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  11. doi request reprint Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
    ..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women...
  12. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  13. doi request reprint Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626
    J Wendall Goodwin
    Cancer Research for the Ozarks, 1730 E Republic Rd, Suite V, Springfield, MO 65804, USA
    J Clin Oncol 26:1650-6. 2008
    ..Prior progestin studies treating hot flashes in women have been short duration and single dose. This study tests the progestin megestrol acetate (MA) at two doses versus placebo over 6 months...
  14. ncbi request reprint Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    Timothy J Whelan
    McMaster University, Hamilton, Canada
    J Clin Oncol 23:6931-40. 2005
    ..To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial...
  15. ncbi request reprint A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...